Cargando…

Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy

We investigated whether responses to as-needed intravitreal aflibercept injections (IAIs) for polypoidal choroidal vasculopathy (PCV) differed among patients based upon drusen characteristics in fellow eyes. 110 eyes from 110 patients with PCV received 3 monthly IAI and thereafter Pro re nata (PRN)...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuda, Yoshiko, Sakurada, Yoichi, Sugiyama, Atsushi, Yoneyama, Seigo, Matsubara, Mio, Kikushima, Wataru, Tanabe, Naohiko, Parikh, Ravi, Kashiwagi, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463500/
https://www.ncbi.nlm.nih.gov/pubmed/32752023
http://dx.doi.org/10.3390/jcm9082459
_version_ 1783577146287980544
author Fukuda, Yoshiko
Sakurada, Yoichi
Sugiyama, Atsushi
Yoneyama, Seigo
Matsubara, Mio
Kikushima, Wataru
Tanabe, Naohiko
Parikh, Ravi
Kashiwagi, Kenji
author_facet Fukuda, Yoshiko
Sakurada, Yoichi
Sugiyama, Atsushi
Yoneyama, Seigo
Matsubara, Mio
Kikushima, Wataru
Tanabe, Naohiko
Parikh, Ravi
Kashiwagi, Kenji
author_sort Fukuda, Yoshiko
collection PubMed
description We investigated whether responses to as-needed intravitreal aflibercept injections (IAIs) for polypoidal choroidal vasculopathy (PCV) differed among patients based upon drusen characteristics in fellow eyes. 110 eyes from 110 patients with PCV received 3 monthly IAI and thereafter Pro re nata (PRN) IAI over 12 months. Patients were classified into 4 groups depending on fellow eye findings. Group 1 (n = 16): pachydrusen; Group 2 (n = 45): no drusen; Group 3 (n = 35): soft drusen; Group4 (n = 14) PCV/scarring. Best-corrected visual acuity improved at 12 months in all groups, but not significantly in Group 1 and Group 4; however, visual improvement was similar among the groups after adjusting baseline confounders. Group 1 had a significantly lower percentage of eyes needing retreatment (all p < 0.001; Group 1: 16.7%; Group 2: 50.8%; Group 3: 80%; Group 4: 85.7%). The mean number of retreatments was least in Group 1 among the groups (all p-value < 0.003; Group 1: 0.50 ± 1.32; Group 2: 1.73 ± 2.08; Group 3:2.71 ± 1.99; Group 3: 2.71 ± 2.16). Patients with pachydrusen in fellow eyes were less likely to require additional IAI following the loading dose and may be ideal candidates for aflibercept monotherapy in their first year.
format Online
Article
Text
id pubmed-7463500
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74635002020-09-04 Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy Fukuda, Yoshiko Sakurada, Yoichi Sugiyama, Atsushi Yoneyama, Seigo Matsubara, Mio Kikushima, Wataru Tanabe, Naohiko Parikh, Ravi Kashiwagi, Kenji J Clin Med Article We investigated whether responses to as-needed intravitreal aflibercept injections (IAIs) for polypoidal choroidal vasculopathy (PCV) differed among patients based upon drusen characteristics in fellow eyes. 110 eyes from 110 patients with PCV received 3 monthly IAI and thereafter Pro re nata (PRN) IAI over 12 months. Patients were classified into 4 groups depending on fellow eye findings. Group 1 (n = 16): pachydrusen; Group 2 (n = 45): no drusen; Group 3 (n = 35): soft drusen; Group4 (n = 14) PCV/scarring. Best-corrected visual acuity improved at 12 months in all groups, but not significantly in Group 1 and Group 4; however, visual improvement was similar among the groups after adjusting baseline confounders. Group 1 had a significantly lower percentage of eyes needing retreatment (all p < 0.001; Group 1: 16.7%; Group 2: 50.8%; Group 3: 80%; Group 4: 85.7%). The mean number of retreatments was least in Group 1 among the groups (all p-value < 0.003; Group 1: 0.50 ± 1.32; Group 2: 1.73 ± 2.08; Group 3:2.71 ± 1.99; Group 3: 2.71 ± 2.16). Patients with pachydrusen in fellow eyes were less likely to require additional IAI following the loading dose and may be ideal candidates for aflibercept monotherapy in their first year. MDPI 2020-07-31 /pmc/articles/PMC7463500/ /pubmed/32752023 http://dx.doi.org/10.3390/jcm9082459 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fukuda, Yoshiko
Sakurada, Yoichi
Sugiyama, Atsushi
Yoneyama, Seigo
Matsubara, Mio
Kikushima, Wataru
Tanabe, Naohiko
Parikh, Ravi
Kashiwagi, Kenji
Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy
title Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy
title_full Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy
title_fullStr Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy
title_full_unstemmed Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy
title_short Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy
title_sort pachydrusen in fellow eyes predict response to aflibercept monotherapy in patients with polypoidal choroidal vasculopathy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463500/
https://www.ncbi.nlm.nih.gov/pubmed/32752023
http://dx.doi.org/10.3390/jcm9082459
work_keys_str_mv AT fukudayoshiko pachydruseninfelloweyespredictresponsetoafliberceptmonotherapyinpatientswithpolypoidalchoroidalvasculopathy
AT sakuradayoichi pachydruseninfelloweyespredictresponsetoafliberceptmonotherapyinpatientswithpolypoidalchoroidalvasculopathy
AT sugiyamaatsushi pachydruseninfelloweyespredictresponsetoafliberceptmonotherapyinpatientswithpolypoidalchoroidalvasculopathy
AT yoneyamaseigo pachydruseninfelloweyespredictresponsetoafliberceptmonotherapyinpatientswithpolypoidalchoroidalvasculopathy
AT matsubaramio pachydruseninfelloweyespredictresponsetoafliberceptmonotherapyinpatientswithpolypoidalchoroidalvasculopathy
AT kikushimawataru pachydruseninfelloweyespredictresponsetoafliberceptmonotherapyinpatientswithpolypoidalchoroidalvasculopathy
AT tanabenaohiko pachydruseninfelloweyespredictresponsetoafliberceptmonotherapyinpatientswithpolypoidalchoroidalvasculopathy
AT parikhravi pachydruseninfelloweyespredictresponsetoafliberceptmonotherapyinpatientswithpolypoidalchoroidalvasculopathy
AT kashiwagikenji pachydruseninfelloweyespredictresponsetoafliberceptmonotherapyinpatientswithpolypoidalchoroidalvasculopathy